Arius Pharmacueticals Inc is categorized under Biological Research in Raleigh, NC and active since 2004.
Arius Pharmacueticals Inc was established in 2004, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Biological Research business, which does work in the B2B market, and is classified as a Biological Research, under code number 541712 by the NAICS.
If you are seeking more information, feel free to contact Mark Sirgo at the company’s single location by writing to 801 Corporate Center Drive # 210, Raleigh, North Carolina NC 27607 or by phoning (919) 582-9050. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Arius Pharmacueticals Inc |
| Contact Person: | Mark Sirgo |
| Address: | 801 Corporate Center Drive # 210, Raleigh, North Carolina 27607 |
| Phone Number: | (919) 582-9050 |
| Website Address: | bdsi.com |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2004 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Biological Research |
| SIC Code: | 8731 |
| NAICS Code: | 541712 |
| Share This Business: |
Arius Pharmacueticals Inc was started in 2004 to provide professional Biological Research under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Mark Sirgo for inquiries that concern Arius Pharmacueticals Inc by calling the company number (919) 582-9050, as your correspondence is most welcome. Additionally, the physical location of the single location of Arius Pharmacueticals Inc can be found at the coordinates as well as the street address 801 Corporate Center Drive # 210 in Raleigh, North Carolina 27607.
For its online presence, you may visit Arius Pharmacueticals Inc’s website at bdsi.com and engage with its social media outlets through on Twitter and on Facebook.